Patents by Inventor Mark A. Gallop

Mark A. Gallop has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240299555
    Abstract: Provided herein are agents and methods for selectively killing senescent cells that are associated with numerous pathologies and diseases, including age-related pathologies and diseases. As disclosed herein, senescent cell-associated diseases and disorders may be treated or prevented by administering at least one senolytic agent or pharmaceutical compositions thereof. The senescent cell-associated diseases or disorders treated or prevented by the agents and methods described herein include, but are not limited to, cardiovascular diseases or disorders, cardiovascular diseases and disorders associated with arteriosclerosis, such as atherosclerosis, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), osteoarthritis, inflammatory or autoimmune diseases or disorders, pulmonary diseases or disorders, neurological diseases or disorders, dermatological diseases or disorders, chemotherapeutic side effects, radiotherapy side effects, metastasis and metabolic diseases.
    Type: Application
    Filed: May 6, 2024
    Publication date: September 12, 2024
    Inventors: Marco Quarta, Mark A. Gallop, Jeffrey R. Jasper, Paul Keitz, Gus Bergnes
  • Publication number: 20240182506
    Abstract: Provided herein are novel sugar derivatives which are intermediates for preparing senolytic agents that selectively kill senescent cells associated with numerous pathologies and discases. including age-related pathologies and discases.
    Type: Application
    Filed: January 3, 2024
    Publication date: June 6, 2024
    Inventors: Paul Keitz, Gus Bergnes, Mark A. Gallop, Marco Quarta
  • Patent number: 11897915
    Abstract: Provided herein are novel sugar derivatives which are intermediates for preparing senolytic agents that selectively kill senescent cells associated with numerous pathologies and diseases, including age-related pathologies and diseases.
    Type: Grant
    Filed: September 13, 2022
    Date of Patent: February 13, 2024
    Assignee: Rubedo Life Sciences, Inc.
    Inventors: Paul Keitz, Gus Bergnes, Mark A. Gallop, Marco Quarta
  • Publication number: 20230321130
    Abstract: Provided herein are senolytic agents for selectively killing senescent cells that are associated with numerous pathologies and diseases, including age-related pathologies and diseases. As disclosed herein, senescent cell-associated diseases and disorders may be treated or prevented by administering at least one senolytic agent or pharmaceutical compositions thereof. The senescent cell-associated diseases or disorders treated or prevented by the methods described herein include, but are not limited to, cardiovascular diseases or disorders, cardiovascular diseases and disorders associated with arteriosclerosis, such as atherosclerosis, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), osteoarthritis, inflammatory diseases or disorders, autoimmune diseases or disorders, pulmonary diseases or disorders, neurological diseases or disorders, dermatological diseases or disorders, chemotherapeutic side effects, radiotherapy side effects, metastasis and metabolic diseases.
    Type: Application
    Filed: April 17, 2023
    Publication date: October 12, 2023
    Inventors: Mark A. Gallop, Julian Klein, Marco Quarta
  • Publication number: 20230201218
    Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.
    Type: Application
    Filed: February 28, 2023
    Publication date: June 29, 2023
    Applicant: Arixa Pharmaceuticals, Inc.
    Inventors: Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton
  • Publication number: 20230137021
    Abstract: Provided herein are agents and methods for selectively killing senescent cells that are associated with numerous pathologies and diseases, including age-related pathologies and diseases. As disclosed herein, senescent cell-associated diseases and disorders may be treated or prevented by administering at least one senolytic agent or pharmaceutical compositions thereof. The senescent cell-associated diseases or disorders treated or prevented by the agents and methods described herein include, but are not limited to, cardiovascular diseases or disorders, cardiovascular diseases and disorders associated with arteriosclerosis, such as atherosclerosis, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), osteoarthritis, inflammatory or autoimmune diseases or disorders, pulmonary diseases or disorders, neurological diseases or disorders, dermatological diseases or disorders, chemotherapeutic side effects, radiotherapy side effects, metastasis and metabolic diseases.
    Type: Application
    Filed: September 13, 2022
    Publication date: May 4, 2023
    Inventors: Marco Quarta, Mark A. Gallop, Jeffrey R. Jasper, Paul Keitz, Gus Bergnes
  • Publication number: 20230096764
    Abstract: Provided herein are novel sugar derivatives which are intermediates for preparing senolytic agents that selectively kill senescent cells associated with numerous pathologies and diseases, including age-related pathologies and diseases.
    Type: Application
    Filed: September 13, 2022
    Publication date: March 30, 2023
    Inventors: Paul Keitz, Gus Bergnes, Mark A. Gallop, Marco Quarta
  • Publication number: 20220324835
    Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.
    Type: Application
    Filed: January 25, 2019
    Publication date: October 13, 2022
    Inventors: Paul A. BARSANTI, Neil F. BENCE, Jennifa GOSLING, Anjanabha SAHA, Asad M TAHERBHOY, Christoph W. ZAPF, Kathleen BOYLE, Mario CARDOZO, Jeffrey MIHALIC, Morgan LAWRENZ, Mark GALLOP, Jilliane BRUFFEY, Thomas CUMMINS, Daniel ROBBINS, Hiroko TANAKA, Chenbo WANG, Frederick COHEN, Wylie PALMER, Arthur T. SANDS, Hunter SHUNATONA
  • Publication number: 20210299154
    Abstract: Provided herein are senolytic agents for selectively killing senescent cells that are associated with numerous pathologies and diseases, including age-related pathologies and diseases. As disclosed herein, senescent cell-associated diseases and disorders may be treated or prevented by administering at least one senolytic agent or pharmaceutical compositions thereof. The senescent cell-associated diseases or disorders treated or prevented by the methods described herein include, but are not limited to, cardiovascular diseases or disorders, cardiovascular diseases and disorders associated with arteriosclerosis, such as atherosclerosis, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), osteoarthritis, inflammatory diseases or disorders, autoimmune diseases or disorders, pulmonary diseases or disorders, neurological diseases or disorders, dermatological diseases or disorders, chemotherapeutic side effects, radiotherapy side effects, metastasis and metabolic diseases.
    Type: Application
    Filed: May 4, 2021
    Publication date: September 30, 2021
    Inventors: Mark A. Gallop, Julian Klein, Marco Quarta
  • Patent number: 11026963
    Abstract: Provided herein are senolytic agents for selectively killing senescent cells that are associated with numerous pathologies and diseases, including age-related pathologies and diseases. As disclosed herein, senescent cell-associated diseases and disorders may be treated or prevented by administering at least one senolytic agent or pharmaceutical compositions thereof. The senescent cell-associated diseases or disorders treated or prevented by the methods described herein include, but are not limited to, cardiovascular diseases or disorders, cardiovascular diseases and disorders associated with arteriosclerosis, such as atherosclerosis, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), osteoarthritis, inflammatory diseases or disorders, autoimmune diseases or disorders, pulmonary diseases or disorders, neurological diseases or disorders, dermatological diseases or disorders, chemotherapeutic side effects, radiotherapy side effects, metastasis and metabolic diseases.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: June 8, 2021
    Assignee: Rubedo Life Sciences, Inc.
    Inventors: Mark A. Gallop, Julian Klein, Marco Quarta
  • Publication number: 20200297733
    Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.
    Type: Application
    Filed: June 8, 2020
    Publication date: September 24, 2020
    Inventors: ERIC M. GORDON, JOHN FREUND, MARK A. GALLOP, MATTHEW ALEXANDER JAMES DUNCTON
  • Patent number: 10722521
    Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: July 28, 2020
    Assignee: ARIXA PHARMACEUTICALS, INC.
    Inventors: Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton
  • Publication number: 20200046724
    Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the f-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.
    Type: Application
    Filed: October 16, 2019
    Publication date: February 13, 2020
    Applicant: ARIXA PHARMACEUTICALS, INC.
    Inventors: ERIC M. GORDON, JOHN FREUND, MARK A. GALLOP, MATTHEW ALEXANDER JAMES DUNCTON
  • Publication number: 20200016185
    Abstract: Provided herein are senolytic agents for selectively killing senescent cells that are associated with numerous pathologies and diseases, including age-related pathologies and diseases. As disclosed herein, senescent cell-associated diseases and disorders may be treated or prevented by administering at least one senolytic agent or pharmaceutical compositions thereof. The senescent cell-associated diseases or disorders treated or prevented by the methods described herein include, but are not limited to, cardiovascular diseases or disorders, cardiovascular diseases and disorders associated with arteriosclerosis, such as atherosclerosis, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), osteoarthritis, inflammatory diseases or disorders, autoimmune diseases or disorders, pulmonary diseases or disorders, neurological diseases or disorders, dermatological diseases or disorders, chemotherapeutic side effects, radiotherapy side effects, metastasis and metabolic diseases.
    Type: Application
    Filed: July 11, 2019
    Publication date: January 16, 2020
    Inventors: Mark A. Gallop, Julian Klein, Marco Quarta
  • Patent number: 10500211
    Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: December 10, 2019
    Assignee: ARIXA PHARMACEUTICALS, INC.
    Inventors: Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton
  • Patent number: 10385014
    Abstract: The disclosures herein relate generally to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, pharmaceutical compositions thereof, methods of making prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, methods of using prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing common diseases and/or disorders such as spasticity and/or acid reflux disease. The disclosures herein also relate to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof which are suitable for oral administration and to sustained release oral dosage forms thereof.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: August 20, 2019
    Assignee: ARBOR PHARMACEUTICALS, LLC
    Inventors: Mark A. Gallop, Fenmei Yao, Maria J. Ludwikow, Thu Phan, Ge Peng
  • Publication number: 20190022102
    Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.
    Type: Application
    Filed: August 29, 2018
    Publication date: January 24, 2019
    Inventors: ERIC M. GORDON, JOHN FREUND, MARK A. GALLOP, MATTHEW ALEXANDER JAMES DUNCTON
  • Patent number: 10085999
    Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: October 2, 2018
    Assignee: ARIXA PHARMACEUTICALS, INC.
    Inventors: Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton
  • Publication number: 20180258032
    Abstract: The disclosures herein relate generally to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, pharmaceutical compositions thereof, methods of making prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, methods of using prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing common diseases and/or disorders such as spasticity and/or acid reflux disease. The disclosures herein also relate to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof which are suitable for oral administration and to sustained release oral dosage forms thereof.
    Type: Application
    Filed: March 7, 2018
    Publication date: September 13, 2018
    Inventors: Mark A. Gallop, Fenmei Yao, Maria J. Ludwikow, Thu Phan, Ge Peng
  • Patent number: 9944592
    Abstract: The disclosures herein relate generally to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, pharmaceutical compositions thereof, methods of making prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, methods of using prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing common diseases and/or disorders such as spasticity and/or acid reflux disease. The disclosures herein also relate to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof which are suitable for oral administration and to sustained release oral dosage forms thereof.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: April 17, 2018
    Assignee: XENOPORT, INC.
    Inventors: Mark A. Gallop, Fenmei Yao, Maria J. Ludwikow, Thu Phan, Ge Peng